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Background: Although the etiology of PD remains unclear, increasing evidence has shown that oxidative stress
plays an important role in its pathogenesis and that of other neurodegenerative disorders. NOX2, a cytochrome
subunit of NOX, transports electrons across the plasma membrane to generate ROS, leading to physiological and
pathological processes. Heme oxygenase-1 (HO-1) can be rapidly induced by oxidative stress and other noxious
stimuli in the brain or other tissues. Astaxanthin (ATX), a carotenoid with antioxidant properties, is 100–1000 times
more effective than vitamin E. The present study investigated the neuroprotective effects of ATX on MPP+-induced
oxidative stress in PC12 cells.
Results: MPP+ significantly decreased MTT levels in a concentration-dependent manner. Hemin, SnPPIX and ATX
didn’t exhibit any cytotoxic effects on PC12 cells. Pretreatment with ATX (5, 10, 20 μM), caused intracellular ROS
production in the MPP+ group to decrease by 13.06%, 22.13%, and 27.86%, respectively. MPP+ increased NOX2,
NRF2 and HO-1 protein expression compared with control (p < 0.05). Co-treatment with hemin or ATX suppressed
NOX2 expression (p < 0.01), and greatly increased NRF2 and HO-1 expression (p < 0.01). MPP+ treatment
up-regulated both NOX2 (p < 0.01) and HO-1 (p < 0.01) mRNA levels. Co-treatment with hemin or ATX significantly
increased HO-1 mRNA levels (p < 0.01), and decreased NOX2 mRNA levels (p < 0.01). MPP+ increased NOX2 and
HO-1 expression with considerable fluorescence extending out from the perinuclear region toward the periphery;
this was attenuated by DPI. Co-treatment with hemin or ATX significantly up-regulated HO-1 expression and
decreased NOX2 expression with considerable fluorescence intensity (stronger than the control and MPP+ groups).
Conclusions: ATX suppresses MPP+-induced oxidative stress in PC12 cells via the HO-1/NOX2 axis. ATX should be
strongly considered as a potential neuroprotectant and adjuvant therapy for patients with Parkinson’s disease.
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Parkinson’s disease (PD) is a progressive, neurodegenera-
tive movement disorder, characterized by the loss of
nigrostriatal dopaminergic neurons. Although the eti-
ology of PD remains unclear, increasing evidence has
shown that oxidative stress plays an important role in its
pathogenesis [1] and that of other neurodegenerative
disorders. Several mechanisms have been proposed to ex-
plain the pathogenesis of PD, including the production of
reactive oxygen species (ROS), generated by dopamine* Correspondence: unionqyye@163.com
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reproduction in any medium, provided the orauto-oxidation, mitochondrial dysfunction, or α-synuclein
deposition [2,3]. Excessive accumulation of ROS, an im-
balance of antioxidant enzymes and activation of the
oxidase system all damage DNA and induce lipid peroxi-
dation and protein modification, subsequently causing
cellular dysfunction and even apoptosis [4,5]. PC12 cells,
derived from a clonal rat pheochromocytoma cell line,
have been widely used as cellular models of Parkinson’s
disease as these cells share features with midbrain
dopaminergic neurons [6,7]. The neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), via its active
metabolite 1-methyl-4-phenylpyridinium ion (MPP+), is
selectively taken up by dopaminergic neurons via the
plasma membrane dopamine transporter [8] impairingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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loss. Further understanding into the mechanisms of
MPP+-induced dopaminergic neuronal death may pro-
vide insights into potential therapeutic targets for PD.
The production of ROS by mitochondria is thought to
be the main cause of oxidative stress. However, a role for
the ROS-generating nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase (NOX) enzymes has recently
emerged. NADPH oxidase plays a critical role in CD200-
CD200R-mediated dopamine neurotoxicity in PD [9].
NOX2 is a cytochrome subunit of NOX that transports
electrons across the plasma membrane to generate ROS
and promotes physiological and pathological processes.
Studies have shown NOX2 expression in several areas
of the adult brain, including the corpus callosum, spinal
cord, hippocampus, cerebral cortex, brainstem, amygdala,
striatum, thalamus, cerebellum, etc. [10]. Activation of
phagocytic NOX2 has been studied mainly in microglia,
where it plays a role in inflammation, but may also con-
tribute to neuronal death in pathological conditions [10].
Thus, microglia-mediated NOX2 activation, caused by
dopaminergic neuron injury, may play a role in the loss of
dopaminergic neurons.
Heme oxygenase-1 (HO-1), a 32-kDa cellular stress re-
sponse protein (also known as Hsp32), can be rapidly
induced by oxidative stress and other noxious stimuli in
the brain or other tissues [11]. HO-1 is the rate-limiting
enzyme in heme degradation and is therefore involved in
the control of cellular heme content. HO-1 has many anti-
oxidant properties, giving the enzyme protective proper-
ties in various models of oxidative injury. Indeed, HO-1
over-expressing mice have decreased oxidative damage
[12]. Increased HO-1 expression has a cytoprotective
effect against MPP+-induced cytotoxicity [13]. NRF2
(NF-E2-related factor) is a transcription factor that
induces the expression of various cytoprotective enzymes.
NRF2 activation and subsequent cytoprotective gene in-
duction promote the restoration of balance between oxi-
dants and antioxidants after an oxidative insult. Studies
have reported that NRF2 can regulate HO-1 protein or
mRNA levels. The coffee diterpene kahweol induces
HO-1 via the PI3K and p38/NRF2 pathways to protect
human dopaminergic neurons from 6-hydroxydopamine
(6-OHDA)-induced oxidative stress [14]. Transfection
with NRF2 siRNA significantly suppressed cigarette smoke
particle-phase extract (CSPE)-enhanced HO-1 protein
levels. Activated NRF2 is recruited to the promoter region
of HO-1, leading to increased expression of HO-1 protein
in human tracheal smooth muscle cells (HTSMCs) [15].
Up-regulation of HO-1 by activation of the NRF2-ARE
signaling pathway attenuates paraquat-mediated oxidative
stress and cell death in dopaminergic PC12 cells [16].
Astaxanthin (3,30-dihydroxy-β,β-carotene-4,40-dione;
ATX; Figure 1), a carotenoid with antioxidantproperties, is 100–1000 times more effective than
vitamin E. ATX is commonly found in crustaceans
such as shrimp and crab, as well as marine organisms
such as salmon, salmon roe, krill and algae. ATX is
found in the free state and in the ester form and also
exists as a chromoprotein. In recent years, a number
of in vitro and in vivo studies of ATX have demon-
strated its antioxidant and neuroprotective effects, for
example in global cerebral ischemia in rats [17]. In
addition, ATX has been shown to inhibit 6-OHDA-
induced neuronal apoptosis [18] and protect PC12
cells against beta-amyloid peptide 25–35-induced cell
apoptosis and death [19]. A study using rats fed
natural ATX revealed ATX crossed the blood–brain
barrier in mammals, extending its antioxidant benefits
into the brain [20]. However, the neuroprotective
action of ATX in PD has yet to be investigated.
The present study investigated the neuroprotective




Dulbecco’s modified Eagle’s medium (DMEM), fetal
bovine serum (FBS), Hank’s balanced salt solution
(HBSS) and antibiotic-antimycotic were purchased from
Gibco BRL (Grand Island, NY, USA), astaxanthin (ATX)
from Wako (Catalog No. 013–23051, Tokyo, Japan),
N-methyl-4-phenylpyridinium (MPP+) ion (No. D048),
the NADPH oxidase inhibitor diphenyleneiodonium
chloride (DPI, No. D2926), the HO inducer hemin
(ferriprotoporphyrin IX chloride, No. 51280) and 3-[4,5-
dimethylthiazol- 2-yl]-2,5- diphenyltetrazolium bromide
(MTT) from Sigma-Aldrich (St. Louis, MO, USA), the
HO inhibitor tin protoporphyrin IX dichloride (SnPPIX,
Cat. No. 0747) from Tocris Bioscience (Abingdon, UK),
40,6-diamidino-2-phenylindole (DAPI) and 20,70-dichlor-
fluorescein-diacetate (DCFH-DA) from Beyotime Institute
of Biotechnology (Shanghai, China), All other chemicals
were purchased from commercial sources.
Cell culture
The rat pheochromocytoma cell line (PC12) was cul-
tured in high glucose DMEM, supplemented with 10%
FBS, 100 U/ml penicillin, and 100 U/ml streptomycin.
The cell line was grown as undifferentiated cells in a
100-mm2 culture dish at 37°C in a humidified incubator
(Forma Scientific, Ohio, USA; Model No. 3130) contain-
ing 5% CO2. When the cells were 70% confluent they
were harvested and dispersed. The well dispersed cells
were then cultured for 24–36 h with an antagonist or
ATX in the presence or absence of MPP+. The cultured
medium was changed every 2–3 d. In some experiments,
cells were pre-treated for 2 h with 20 μM hemin, 10 μM
Figure 1 Chemical structure of Astaxanthin.
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with MPP+ (500 μM) for 24 h. Control cells were cul-
tured without MPP+.Cell viability assay
MTT, absorbed into the cell and eventually the mito-
chondria, is broken down into formazan by mito-
chondria succinate dehydrogenase. Accumulation of
formazan reflects the activity of mitochondria directly
and the cell viability indirectly. Cell viability was mea-
sured by the MTT assay. PC12 cells were seeded on
96-well plates at a density of 8×103 cells/well, cul-
tured, differentiated, and treated according to the
above methods. A total of 20 μl of MTT was added
at a concentration of 0.5 mg/ml after media (200 μl)
was added to each well. The plates were incubated at
37°C for 4 h to dissolve the formazan that had
formed. The solution (220 μl) was removed from each
well and 150 μl of dimethyl sulfoxide was added.
Reduced MTT was measured on an ELISA reader
(Bio-Rad, Hercules, CA, USA) at a wavelength of 570
nm. Values for each treatment group are expressed as
a percentage of the control value.Detection of intracellular ROS
The DCFH-DA assay was used to measure ROS produc-
tion in differentiated PC12 cells treated with MPP+.
DCFH-DA is a fluorescent dye that crosses the cell
membrane and is enzymatically hydrolyzed by intracellu-
lar esterases to non-fluorescent DCFH. The cells were
plated at a density of 4×105 cells per 6-well dish. Differ-
entiated PC12 cells were pretreated with DPI (1 μM)
and ATX (5, 10, 20 μM) in medium for 2 h, then
exposed to MPP+ (500μM) for 24 h. The cells were incu-
bated with DCFH-DA at a final concentration of 10 μM
in high glucose DMEM without FBS for 20 min at 37°C
and washed three times with DMEM. ROS levels were
measured using a flow cytometer (FACScalibur, Becton
Dickinson, San Jose, CA, USA) with excitation and emis-
sion wavelengths set at 475 and 525 nm, respectively.
For each analysis, 10,000 events were recorded. The
value for each treatment group was converted to a per-
centage of the control value.Western blot analysis
The cells, plated at a density of 4×105 cells per 6-well
dish, were treated with various concentrations of antag-
onist or ATX in media with or without MPP+ (500μM)
for 24 h. For whole cell lysates, the cells were washed
twice with ice cold PBS, harvested in RIPA lysis buffer
(50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS, sodium orthovana-
date, sodium fluoride, EDTA, 0.5 mM PMSF), incubated
for 10 min on ice, centrifuged at 12,000 × g for 10 min
at 4°C and the supernatant, containing cell lysates, col-
lected. Equal amounts of protein (50 μg) from the cell
extracts in each treatment condition were separated
using 10% sodium dodecyl sulfate (SDS) polyacrylamide
gel electrophoresis (PGE), then transferred electrophor-
etically onto polyvinylidene fluoride (PVDF) (Millipore,
Carrigtwohill, Ireland). The blots were blocked by incu-
bation in 5% (w/v) non-fat dry milk in PBS with 0.1%
Tween 20 (PBS-T) for 4 h. After incubation with a pri-
mary antibody [anti-NOX2 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) 1:200 and anti-HO-1 (Stressgen,
Ann Arbor, MI, USA) 1:1000] in PBS-T at 4°C overnight,
the membranes were washed three times in PBS-T for
10 min. Subsequently, the membranes were incubated
for 1 h in PBS-T containing the appropriate horseradish
peroxidase-conjugated secondary antibody [anti-mouse
IgG and anti-rabbit IgG (Beyotime Institute of Biotech-
nology, China) 1:2000]. The immunoreactive bands were
visualized and quantified using the Luminata Forte West-
ern HRP substrate (Millipore, Billerica, MA, USA). Protein
levels were normalized to the housekeeping protein β-
actin (Beyotime Institute of Biotechnology, Shanghai,
China) 1:1000to adjust for variability of protein loading
and expressed as a percentage of the vehicle control.
Immunofluorescence confocal microscopy
PC12 cells were permeabilized and fixed with 4% parafor-
maldehyde and 0.5% Triton X-100. Slides were blocked
with 1% normal donkey serum (Merck, Darmstadt,
Germany) in PBS for 30 min at room temperature. Cells
were washed with 0.1% BSA (Beyotime Institute of Bio-
technology, Shanghai, China)/PBS three times with gentle
shaking, then incubated with the primary antibodies
diluted (HO-1 1:1000 and NOX2 1:200) in 0.1% BSA/PBS
at 4°C overnight. Labeled donkey anti–rabbit IgG or anti-
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used as the secondary antibody and incubated in the dark
for 2 h at room temperature. Specific antibody binding
was detected by Alexa Fluor 488- (green label) and Alexa
Fluor 594- (red label) conjugated extravidin (Sigma-
Aldrich,St. Louis, MO, USA). Confocal microscopy was
performed using the Leica SP5 confocal microscopy
system (Leica Microsystems CMS GmbH, Mannheim,
Germany). Optical sections were taken at 0.5 μm
intervals and images were captured and stored digit-
ally for analysis. Fluorescence intensity was quantified
from at least three random fields (1024 × 1024 pixels;
310 × 310 μm) per slide, three slides per experimen-
tal condition, and repeated three times using separate
cell cultures.
Quantitative real-time PCR analysis
Total RNA from PC12 cells was isolated according
to the manufacturer’s protocol using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). Total RNA purity
and integrity was confirmed using the ND-1000
NanoDrop (NanoDrop Technologies, Wilmington,
USA) and 2100 Bioanalyzer (Agilent, California,
USA). RNA (1 μg) was reverse-transcribed into
cDNA in a total volume of 20 μl using the Rever-
tAidTM First Strand cDNA Synthesis Kit (Fermentas,
St. Leon-Rot, Germany). The cDNA (2 μl) was amp-
lified with a sequence detection system (ABI Prism
7500) in a total volume of 20 μl containing 10 μl of
the FastStart Universal SYBR Green Master Mix
(ROX) (Roche, Penzberg, Germany) and each primer
at 0.3 μM. Forward and reverse primers for spe-




TAAGGT-30)] and β-actin [F1(50-CACCCGCGAGTA
CAACCTTC-30) and [R1(50- CCCATACCCACCAT
CACACC-30)] were designed, eliminating the possi-
bility of amplifying genomic DNA. Quantitative real-
time PCR was performed using the ABI prism 7500
HT sequence detection system (Applied Biosystems,
Foster City, CA, USA) based on the 59-nuclease
assay [21] for the various genes indicated and the
housekeeping gene GAPDH. Relative expression was
calculated using the ΔΔCt method [22], and passed
the validation experiment. The results are expressed
as an average of triplicate samples of at least three
independent experiments for control and treated
cells.
Statistical analysis
All statistical analyses were carried out using one-way
ANOVAs with repeated measures followed by Scheffe’spost hoc tests. A p value below 0.05 was deemed statisti-
cally significant.
Results
Effects of MPP+, hemin , SnPPIX, DPI and ATX on cell
viability
To evaluate the viability of differentiated PC12 cells after
exposure to oxidative injury, differentiated PC12 cells
were treated with different concentrations of MPP+
(125–2000 μmoL/L) for 24 h. After washing, and follow-
ing 24 h incubation, cell viability was measured using
the MTT assay. MPP+ significantly decreased MTT
levels, indicating a lower cell count, in a concentration-
dependent manner (Figure 2A). Treatment with a con-
centration of 500μΜ of MPP+ for 24 h was selected for
subsequent experiments as it reduced cell viability to
approximately 44% of control (p < 0.01, Figure 2A).
Next, the effects of hemin, SnPPIX, DPI and ATX on
cell viability were investigated. Hemin didn’t exhibit any
cytotoxic effects on PC12 cells at concentrations ranging
from 5–40 μΜ (p > 0.05, Figure 2B), while SnPPIX and
ATX did not significantly alter cell viability at concentra-
tions ranging from 1.25–20 μΜ (p > 0.05, Figure 2C).
For experimental testing, a concentration of 20 μΜ for
hemin, 10 μΜ for SnPPIX and 10 μΜ ATX were
selected. The most commonly used NOX inhibitor is
DPI. At low concentrations (1 μΜ), DPI attenuates the
viability of differentiated PC12 cells, while at higher con-
centrations (1–16 μΜ) the effect of DPI on cell viability
is more significant (Figure 2D). A concentration of 1
μΜ, which reduced cell viability by approximately 4.2%
compared with control (p = 0.075, Figure 2D), was
selected to block expression of NOX2.
Effect of ATX on MPP+-induced oxidative stress
The events involved in MPP+-induced oxidative stress
were evaluated to determine the amount of intracellular
ROS production and the effect of ATX on ROS produc-
tion. ROS production was measured using DCFH-DA.
As shown in Figure 3, the results show MPP+ increased
ROS production by 25.21%, which was inhibited by DPI.
Pretreatment with 5, 10 and 20 μM ATX caused intra-
cellular ROS production in the MPP+ group to decrease
by 13.06%, 22.13% and 27.86%, respectively. ATX alone
attenuated ROS production by 6.77%.
Effects of hemin, SnPPIX and DPI on MPP+-induced NOX2,
NRF2 and HO-1 levels in PC12 cells
Differentiated PC12 cells were pretreated with hemin,
SnPPIX and DPI in medium for 2 h and exposed to
MPP+ (500 μM) for 24 h. To determine the relationship
between NOX2 and HO-1 expression, PC12 cells were
treated with control, MPP+ (500 μM), MPP+ (500 μM)
plus hemin (20 μM), MPP+ (500 μM) plus hemin
Figure 2 Effects of MPP+, hemin, SnPPIX, DPI and ATX on cell viability. Cells were treated with different concentrations of MPP+, hemin,
SnPPIX, DPI and ATX for 24 h, after which the MTT assay was performed. (A) MPP+ (0–2000 μΜ); (B) Hemin (0–40 μΜ); (C) SnPPIX and ATX
(0–20 μΜ); (D) DPI (0–16 μΜ). Relative cell survival values are expressed as a percentage of the control value, *p < 0.05 vs. untreated control,
**p < 0.01 vs. untreated control, # p < 0.05 vs. MPP+ (500 μΜ) treatment only, ## p < 0.01 vs. MPP+ (500 μΜ) treatment only.
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DPI (1 μM). Protein expression of NOX2, NRF2 and
HO-1 was determined by western blot analysis. As
shown in Figure 4A, MPP+ increased NOX2 expression
compared with control (p < 0.05, Figure 4A and
Figure 5A). Co-treatment with hemin suppressed NOX2
expression compared with control (p < 0.01). Co-
treatment with hemin and SnPPIX increased NOX2
expression compared with control (p < 0.01). Finally,
co-treatment with the NADPH inhibitor DPI decreased
NOX2 expression compared with the MPP+ treated
group (p < 0.05). Increased NRF2 and HO-1 expressionis shown following MPP+ treatment for 24 h compared
with control (p < 0.01), indicating that MPP+ enhanced
NOX2, NRF2 and HO-1 expression in PC12 cells. Co-
treatment with hemin greatly increased HO-1 expression
compared with control (100–168.9%) (p < 0.01, Figure 4A),
Finally, although co-treatment with SnPPIX enhanced HO-
1 expression, the effect was not significant (p = 0.091,
Figure 4A).
To determine whether the relationship between NOX2
and HO-1 expression occurred at the transcriptional
level, NOX2 and HO-1 mRNA expression was deter-
mined using quantitative real-time PCR. Our results
Figure 3 ATX attenuates the generation of intracellular ROS by MPP+-induced oxidative stress in PC12 cells. PC12 cells treated groups:
Data.01: Negative control without DCFH-DA; Data.02: Positive control with Rosup; Data.03: control; Data.04: MPP+ (500μM); Data.05: MPP+ (500μM)
and ATX (5μM); Data.06: MPP+ (500μM) and ATX (10μM); Data.07: MPP+ (500μM) and ATX (20μM); Data.08: ATX (10μM); Data.09: MPP+ (500μM)
and DPI (1μM). Intracellular ROS generation was determined by DCFH-DA fluorescence.
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(from 100% control to 243.5%, p < 0.01, Figure 4B) and
HO-1 mRNA (from 100% control to 137.1%, p < 0.01,
Figure 4B) levels. Co-treatment with hemin signifi-
cantly increased HO-1 mRNA levels by 663% vs. con-
trol and 626% vs. the MPP+ group (p < 0.01,
Figure 4B), and decreased NOX2 mRNA levels by53.5% vs. the MPP+ group (p < 0.01, Figure 3B). Co-
treatment with hemin and SnPPIX decreased HO-1
mRNA levels by 335% vs. the MPP+ plus hemin
group and increased NOX2 expression by 58% vs. the
MPP+ plus hemin group (p < 0.01, Figure 4B). Finally,
co-treatment with DPI did not alter NOX2 mRNA
levels compared with control (p = 0.106). However,
Figure 4 (See legend on next page.)
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Figure 4 Effects of hemin, SnPPIX and DPI on MPP+-induced NOX2, NRF2 and HO-1 levels in PC12 cells. The groups are C: Control; M:
MPP+ (500 μM); M+H: MPP+ (500 μM) plus hemin (20 μM); MHS: MPP+ (500 μM) plus hemin (20 μM) and SnPPIX (10 μM); MD: MPP+ (500 μM)
plus DPI (1 μM). (A). The protein expression of NOX2, NRF2 and HO-1 was determined by western blot analysis; (B). NOX2 and HO-1 mRNA levels
were determined by quantitative real-time PCR; (C).
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110% compared with the MPP+ group (p < 0.01,
Figure 4B).
We then performed immunofluorescent double staining
to examine the subcellular localization and expression ofFigure 5 The subcellular localization and expression of HO-1 and NOX
Control; M: MPP+ (500 μM); M+H: MPP+ (500 μM) plus hemin (20 μM); MHS
(500 μM) plus DPI (1 μM). Confocal microscopic images of the subcellular l
of MPP+ and other reagents to PC12 cells, NOX2 (Alexa Fluor 594, red fluor
counterstained with DAPI (blue) are shown.HO-1 and NOX2, following administration of MPP+ and
other reagents (Figure 5). Under normal growth condi-
tions, NOX2 and HO-1 were detected in the perinuclear
region. MPP+ treatment increased NOX2 expression, with
significant fluorescence extending out toward the peri-2 following administration of MPP+ and hemin. The groups are C:
: MPP+ (500 μM) plus hemin (20 μM) and SnPPIX (10 μM); MD: MPP+
ocalization and expression of HO-1 and NOX2. After the administration
escence), HO-1 (Alexa Fluor 488, green fluorescence), and nuclei
Figure 6 (See legend on next page.)
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Figure 6 Effects of ATX on MPP+-induced NOX2, NRF2 and HO-1 levels in PC12 cells. The groups are C: Control; M: MPP+ (500 μM); M+A:
MPP+ (500 μM) plus ATX (10 μM); MAS: MPP+ (500 μM) plus ATX (10 μM) and SnPPIX (10 μM); MD: MPP+ (500 μM) plus DPI (1 μM), A: ATX
(10 μM). (A). The protein expression of Nox2, NRF2 and HO-1 was determined by western blot analysis; (B). NOX2 and HO-1 mRNA levels were
determined by quantitative real-time PCR.
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significantly upregulated HO-1 expression, with stronger
fluorescence intensity compared with both the control
and MPP+ groups, and significantly decreased NOX2 ex-
pression. Both hemin-induced effects were attenuated by
SnPPIX treatment (Figure 5). The results indicate that
MPP+ treatment upregulated NOX2, NRF2 and HO-1 ex-
pression at both the mRNA and protein levels.
Effects of ATX on MPP+-induced changes in NOX2, NRF2
and HO-1 levels in PC12 cells
Previous findings have shown that ATX treatment alters
the expression of the antioxidant enzyme HO-1, protects
neurons against Aβ-induced cytotoxicity [23], and pro-
tects against oxygen-glucose deprivation-induced oxida-
tive stress-dependent injury [18]. We first investigated
the possibility that ATX might alter the expression of
NOX2. Differentiated PC12 cells were pretreated with
ATX, SnPPIX and DPI in the medium for 2 h then
exposed to MPP+ (500 μM) for 24 h. To determine
whether ATX enhances HO-1 expression and inhibits
NOX2 expression to protect against MPP+-mediated
cytotoxicity in PC12 cells, cells were treated with
control, MPP+ (500 μM), MPP+ (500 μM) plus ATX
(10 μM), MPP+ (500 μM) plus ATX (10 μM) and
SnPPIX (10 μM), MPP+ (500 μM) plus DPI (1 μM), and
ATX(10 μM). As shown in Figure 6A, MPP+ increased
NOX2 expression compared with control (p < 0.05,
Figure 3A and Figure 6A). Co-treatment with ATX
decreased NOX2 expression compared with the MPP+
group (p < 0.01), while co-treatment with the NADPH
inhibitor DPI significantly decreased NOX2 expression
compared with the MPP+ group (p < 0.01). MPP+ (500
μM) treatment of PC12 cells for 24 h increased NRF2
and HO-1 expression compared with control (p < 0.01).
Co-treatment with ATX significantly increased both
HO-1 (100–221.5%) and NRF2 expression (100–274.8%)
compared with control (p < 0.01, Figure 6A). These
increases were attenuated by SnPPIX. Finally, ATX treat-
ment alone did not alter NRF2 expression (p = 0.536,
Figure 6A).
To examine whether ATX affects NOX2 and HO-1
expression at the transcriptional level, NOX2 and HO-1
mRNA expression was determined by quantitative real-
time PCR. It revealed that co-treatment with MPP+ and
ATX significantly increased HO-1 mRNA levels by 117%
vs. the MPP+ group (p < 0.01, Figure 6B) and decreased
NOX2 mRNA levels by 24.4% vs. the MPP+ group(p < 0.01, Figure 6B). Co-treatment with MPP+, ATX
and SnPPIX decreased HO-1 mRNA levels by 121% vs.
the MPP+ plus ATX group and increased NOX2 expres-
sion by 34% vs. the MPP+ plus ATX group
(p < 0.01, Figure 6B). Co-treatment with DPI decreased
NOX2 mRNA levels compared with the MPP+ group
(p < 0.01, Figure 6B). Finally, ATX treatment alone
decreased NOX2 and HO-1 mRNA levels by 11.8% com-
pared with control (p < 0.01, Figure 6B).
Finally, we analyzed confocal microscopic images of
HO-1 and NOX2 subcellular localization and expression
after treatment with MPP+ and other reagents (Figure 7).
In MPP+-induced PC12 cells, MPP+ increased NOX2
expression with considerable fluorescence extending out
from the perinuclear region toward the periphery, which
was attenuated by DPI (Figure 7). MPP+ also increased
HO-1 expression. Co-treatment with ATX signifi-
cantly up-regulated HO-1 expression, with considerable
fluorescence intensity (stronger than the control and
MPP+ groups), which was attenuated by SnPPIX. Finally,
co-treatment with ATX significantly decreased NOX2
expression (Figure 7).Discussion
There is increasing evidence that oxidative stress plays a
key role in the pathogenesis of PD. The present study
was designed to elucidate the potential molecular
mechanisms and antioxidant effects of ATX, a natural
carotenoid found in aquatic animals, in an in vitro
model of PD. We tested the protective effects of ATX
on MPP+-induced cytotoxicity. We found that ATX pre-
treatment significantly reduced oxidative stress in PC12
cells treated with MPP+.
NOX2 plays a key role in microglia-mediated dopa-
minergic neurotoxicity, such as exposure to rotenone,
LPS, MPTP/MPP+, 6-OHDA and angiotensin II, which
induces TH-positive selective neuronal death in the mid-
brain [24]. NOX2-deficient mice are protected against
dopaminergic neurotoxicity in an MPTP-induced PD
mouse model. Dopamine degeneration decreased by 20%
in MPTP-treated NOX2−/− mice compared with the
wild-type control group [25]. NOX2 is highly relevant to
nervous system diseases, as it regulates the growth, pro-
liferation, activation and apoptosis of neurons, making
NOX2 suppression a promising therapeutic strategy. In
our study, MPP+ significantly increased the level of
NOX2 expression, which was subsequently attenuated
Figure 7 The subcellular localization and expression of HO-1 and NOX2 following administration of MPP+ and ATX. The groups are C:
Control; M: MPP+ (500 μM); M+A: MPP+ (500 μM) plus ATX (10 μM); MAS: MPP+ (500 μM) plus ATX (10 μM) and SnPPIX (10 μM); MD: MPP+
(500 μM) plus DPI (1 μM), A: ATX (10 μM). Confocal microscopic images of the subcellular localization and expression of HO-1 and NOX2. After
administration of MPP+ and other reagents to PC12 cells, NOX2 (Alexa Fluor 594, red fluorescence), HO-1 (Alexa Fluor 488, green fluorescence),
and nuclei counterstained with DAPI (blue) are shown.
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specific inhibitor of NOX but acts on all flavoproteins.
Induction of HO-1 inhibits NOX activity in macro-
phages [26], although the mechanism by which HO-1
modulates NOX activity is not totally clear. The inhibi-
tory effect of HO-1 has been observed in both the aorta
and kidney, tissues in which NOX activation is a major
source of oxidative stress [27]. Hemin decreases cardiac
oxidative stress, involving PI3Kinase/Akt pathway signal-
ing regulation via HO-1/BVR over-expression and modi-
fying NOX activation [28]. In this study, we provide
direct evidence that HO-1 modulates NOX2 activity.
Hemin, as an HO-1 inducer, can increase HO-1 and
NRF2 levels. Our study found that hemin significantly
decreased NOX2 activity compared with the MPP+
group; this decrease was subsequently attenuated by
SnPPIX treatment (Figure 4, 5). The present study
suggests that over-expression of HO-1 limits oxidative
damage mediated by NOX2 activation in MPP+-treated
PC12 cells. This is an important mechanism underlying
the neuroprotective effects of HO-1 and NRF2, proposed
by several in vitro and in vivo studies. Studies have
shown that up-regulation of HO-1 expression and the
subsequent increase in HO activity may confer an adap-
tive neuroprotective response to oxidative insults both
in vitro and in vivo, mediated by the activation of NRF2
[29,30]. Indeed, in a study using the acute MPTP model,
it was shown that NRF2−/− mice are more sensitive to
MPTP [31].
ROS have multiple effects on cell function, depending
on the amount and subcellular location of the ROS gen-
erated. Controlled intracellular ROS production from
NOX is necessary for normal cellular development and
function [32], whereas excessive ROS generation is
implicated in myocardial hypertrophy and heart failure
[33]. Some studies have reported that ROS are involved
in the apoptotic mechanism of MPP+-mediated neuro-
toxicity [34]. As mentioned previously, data from this
study showed that treatment with MPP+ results in a sig-
nificant increase in ROS, while pretreatment with ATX
and DPI significantly suppressed ROS-generation in PC12
cells in a concentration-dependent manner compared with
both the control and the MPP+-induced oxidative injury
groups (Figure 3). We found that ATX exhibited a signifi-
cant protective effect against MPP+-induced toxicity with
no/little toxicity to PC12 cells. In addition, ATX protected
neuronal cells against oxidative damage [35].
Findings from a previous study showed that ATX
induced levels of HO-1, an antioxidant phase II enzyme,
and NRF2 in vitro. ATX increased the nuclear levels of
NRF2 and the associated protective enzymes HO-1 and
NQO-1 in rat liver, and it was demonstrated that the
protective properties of ATX are mediated by the
NRF2–ARE pathway [36]. In addition, ATX inducedHO-1 protein expression in SH-SY5Y cells, protecting
against Aβ25–35-mediated cytotoxicity [24]. In keeping
with these findings, our study showed that ATX, a
powerful antioxidant, significantly increased NRF2 and
HO-1 protein and mRNA expression when cells were
exposed to MPP+. In addition, pretreatment with ATX
significantly suppressed NOX2 protein and mRNA ex-
pression compared with the MPP+ group; this suppres-
sion was attenuated by SnPPIX treatment (Figure 6, 7).
The results indicate that ATX increased HO-1 and
NFR2 protein expression and decreased NOX2 expres-
sion, protecting against MPP+-induced cytotoxicity in
PC12 cells. NOX2 expression was inhibited by ATX and
DPI, and over-expression of HO-1 decreased NOX2 ex-
pression. We found that NOX2 levels were increased in
PC12 cells following MPP+ administration and attenu-
ated by ATX pretreatment, which induced HO-1 expres-
sion. However, when PC12 cells were cultured in normal
growth conditions, ATX did not up-regulate HO-1 and
NFR2 expression. The neuroprotective effects of ATX
have been reported in several studies using other experi-
mental models [37-39]. Moreover, dietary ATX has been
shown to regulate immune responses, oxidative damage
and inflammation in humans [40].
Conclusions
Our results show that ATX protects against MPP+-induced
oxidative stress via the HO-1/NOX2 axis in a cell model of
PD. Our findings suggest that the molecular mechanisms
responsible for ATX’s neuroprotection are the suppression
of ROS generation, the induction of HO-1 levels and the
inhibition of NOX2 expression. Taken together, our data
suggest that ATX is a viable neuroprotectant and a poten-
tial adjuvant therapy for patients with Parkinson’s disease.
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